Mineralys Therapeutics’ Experimental Drug Achieves Primary Goal in Hypertension Trials

Mineralys Therapeutics announced today that its experimental drug has met the primary endpoint of lowering blood pressure in patients with uncontrolled or resistant hypertension, according to results from both late-stage and mid-stage clinical trials.

The drug, an aldosterone synthase inhibitor designed to block the production of aldosterone (a hormone that plays a key role in regulating blood pressure) demonstrated statistically significant reductions in systolic blood pressure. In the late-stage trial, patients experienced a notable decrease in systolic pressure by week six, with the benefits sustained through week 12. The mid-stage study yielded similarly promising results, reinforcing the drug’s potential effectiveness in this difficult-to-treat patient population.

These positive outcomes build on earlier Phase 2 trial results, which had already indicated a robust, double-digit reduction in systolic blood pressure among patients with resistant hypertension. Notably, individuals with concomitant obesity appeared to benefit even more from the treatment, suggesting a potential advantage in this subgroup.

Mineralys Therapeutics’ Chief Medical Officer commented, “Achieving these results is a critical step forward in providing a new therapeutic option for patients who have not responded adequately to current hypertension treatments.” The company plans to continue advancing the drug through the clinical development process, with hopes of addressing a significant unmet need in cardiovascular care.

The breakthrough is seen as an important milestone in the ongoing battle against hypertension, a major risk factor for heart disease, stroke, and other cardiovascular complications that collectively impose a substantial economic burden on healthcare systems globally.